Canaccord Genuity Gives Buy Rating to Teva Pharmaceutical Industries Ltd (TEVA) Posted by Tammy Falkenburg Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA)‘s stock had its “buy” rating reiterated by investment...[read article]     90-week data suggest sustained glucose reduction&hellip Featured In: Eli Lilly These new findings provide additional information about the use of empagliflozin in type 2 diabetes, and support... [read article]